Myelodysplastic Syndrome (RAEB-II) Development 2 Months after Chemotherapy for a Primary Non-seminomatous Mediastinal Germ Cell Tumor.
10.3904/kjm.2016.90.5.460
- Author:
Bumhee YANG
1
;
Sunhye SHIN
;
Jihye KIM
;
Minsun KIM
;
Silvia PARK
;
Jun Ho JANG
;
Chul Won JUNG
Author Information
1. Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Publication Type:Case Report
- Keywords:
Mediastinal germ cell tumor;
Myelodysplastic syndromes;
Therapy-Related
- MeSH:
Anemia, Refractory;
Bone Marrow Examination;
Chromosome Aberrations;
Cisplatin;
Drug Therapy*;
Etoposide;
Germ Cells*;
Hematologic Neoplasms;
Humans;
Ifosfamide;
Myelodysplastic Syndromes*;
Neoplasms, Germ Cell and Embryonal*;
Paclitaxel;
Young Adult
- From:Korean Journal of Medicine
2016;90(5):460-463
- CountryRepublic of Korea
- Language:English
-
Abstract:
Here, we report on a 20-year-old patient with a primary nonseminomatous mediastinal germ cell tumor (MGCT) who developed myelodysplastic syndrome (MDS) 2 months following chemotherapy with cisplatin, etoposide, ifosfamide, and paclitaxel. Bone marrow examinations revealed that the MDS was a refractory anemia with excess type II blasts and complex chromosomal abnormalities. With the onset of MDS occurring rapidly following chemotherapy, it is unlikely to have been caused by the therapy. We discuss the association between primary nonseminomatous MGCTs and hematological malignancies, including the possibility of a common clonal origin.
